Folate Receptor Autoantibody Test (FRAT® Test)
  info@fratnow.com   |     610-441-9050   |   A test by ReligenDX

Early Detection - Early Intervention - Optimal Outcomes

The early detection of folate receptor autoantibodies is necessary because it can lead to timely diagnosis and appropriate management of conditions associated with these autoantibodies. Folate receptor autoantibodies have been found in Cerebral Folate Deficiency Syndrome, Autism Spectrum Disorders, Schizophrenia, Depression and Neural Tube Defects, among other neurodevelopmental disorders.

FRAT® - developed in the lab of Dr. Edward Quadros at the State University of NY (SUNY Downstate) is the only assay available that can screen for BOTH blocking and binding folate receptor autoantibodies. FRAT®, as published in the New England Journal of Medicine, and used in numerous clinical trials, is the world’s leading diagnostic to detect these specific autoantibodies.

The timely initiation of appropriate treatment, such as alternate reduced folates and/or dietary adjustments, may lead to optimal outcomes and improved overall prognosis for the individual.

As with any medical test, the interpretation of the results and the subsequent treatment plan should be discussed with a qualified healthcare professional.

Science

Science

We continuously research the significance of folate receptor autoantibodies and their implications in various neurodevelopment and neuropsychiatric disorders.

Lives Tranformed by FRAT®

Autism Awareness